Labmaster LUCIA™ CRP

Launched 2021

Labmaster LUCIA™ MxA

Launched 2022

Labmaster LUCIA™ SARS-CoV-2 IgG (NP)

for the qualitative determination of present or past immune response to SARS-CoV-2 virus exposure in whole blood samples.

Test pipeline

Labmaster LUCIA™ SARS-CoV-2 IgG (RBD), in development

for the qualitative determination of present or past immune response to SARS-CoV-2 virus exposure or vaccination efficiency in whole blood samples. The test is suited for monitoring COVID-19 vaccines that are based on SARS-CoV-2 spike-protein producing systems.

Labmaster LUCIA™ SARS-CoV-2 (NAB), in develoment

for the qualitative determination of SARS-CoV-2 neutralizing antibodies (NAB)  in the whole blood samples.

Labmaster LUCIA™ HbA1c (Glycated Hemoglobin), in development

for the quantitative determination of Hemoglobin A1c in whole blood samples